https://scholars.lib.ntu.edu.tw/handle/123456789/635146
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | WANG-HUEI SHENG | en_US |
dc.contributor.author | SZU-MIN HSIEH | en_US |
dc.contributor.author | SHAN-CHWEN CHANG | en_US |
dc.date.accessioned | 2023-09-06T08:41:14Z | - |
dc.date.available | 2023-09-06T08:41:14Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 09296646 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/635146 | - |
dc.description.abstract | The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global health crisis. The specific characteristics of aerosol transmission in the latent period and the contagiousness of SARS-CoV-2 lead to rapid spread of infection in the community. Vaccination is the most effective method for preventing infection and severe outcomes. As of December 1, 2022, 88% of the Taiwanese population had received at least two doses of COVID-19 vaccines. Heterologous vaccination with ChAdOx1-mRNA-based or ChAdOx1-protein-based vaccines has been found to elicit higher immunogenicity than homologous vaccination with ChAdOx1-ChAdOx1 vaccines. A longitudinal cohort study revealed that 8-12-week intervals between the two heterologous vaccine doses of the primary series led to good immunogenicity and that the vaccines were safe. A third booster dose of mRNA vaccine is being encouraged to evoke effective immune responses against variants of concern. A novel domestic recombinant protein subunit vaccine (MVC-COV1901) was manufactured and authorized for emergency use in Taiwan. It has shown a good safety profile, with promising neutralizing antibody titers against SARS-CoV-2. Given the global pandemic due to emerging novel variants of SARS-CoV-2, booster COVID-19 vaccines and appropriate intervals between booster doses need to be investigated. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Journal of the Formosan Medical Association = Taiwan yi zhi | en_US |
dc.subject | Coronavirus disease 2019 (COVID-19); Immune response; Messenger RNA vaccine; Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) | en_US |
dc.title | Achievements of COVID-19 vaccination programs: Taiwanese perspective | en_US |
dc.type | journal article | en |
dc.type | review | en_US |
dc.identifier.doi | 10.1016/j.jfma.2023.04.017 | - |
dc.identifier.pmid | 37142477 | - |
dc.identifier.scopus | 2-s2.0-85156159652 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85156159652 | - |
dc.relation.pages | S70 | en_US |
dc.relation.journalvolume | 123 | en_US |
dc.relation.pageend | S76 | en_US |
item.openairetype | journal article | - |
item.openairetype | review | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Medical Education-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Office of the Vice President | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Medical Education and Bioethics | - |
crisitem.author.orcid | 0000-0002-5605-7853 | - |
crisitem.author.orcid | 0000-0002-1879-4086 | - |
crisitem.author.orcid | 0000-0001-6505-4139 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | Administrative Unit | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。